Financial
News release
TopTOKYO, JAPAN – December 6, 2022 – Terumo Corporation (TSE: 4543) today announced the launch of “G-Lasta® Subcutaneous Injection 3.6 mg BodyPod”, a drug-device combination product co-developed with Kyowa Kirin Co., Ltd. (TSE: 4151). The product will be marketed in Japan by Kyowa Kirin from December 6, 2022.
G-Lasta® Subcutaneous Injection 3.6 mg BodyPod is a combination product of an automated injection device and G-Lasta® [KRN125, generic name: pegfilgrastim (genetical recombination)]. Kyowa Kirin has been marketing G-Lasta® since 2014, and the drug is administered to patients undergoing chemotherapy to decrease the incidence of febrile neutropenia*.
With the G-Lasta® Subcutaneous Injection 3.6 mg BodyPod, the injection device is activated and attached to the patient's body at the hospital on the day of chemotherapy. Then, the drug is automatically administered approximately 27 hours later. In principle, G-Lasta® is typically administered at hospitals at least one day after chemotherapy. The newly developed combination product allows patients to skip the additional outpatient visit required for the administration of G-Lasta®, and helps reduce the burden on patients.
Terumo has developed the automated injection device of the G-Lasta® Subcutaneous Injection 3.6 mg BodyPod by leveraging its expertise in medical device engineering. Noritsugu Fujita, Executive Officer, Division President of Pharmaceutical Solutions comments, “We will continue to provide unique solutions to pharmaceutical companies to maximize the value of their drugs and contribute to increase patients’ quality of life”.
G-Lasta® Subcutaneous Injection 3.6 mg BodyPod is a combination product of an automated injection device and G-Lasta® [KRN125, generic name: pegfilgrastim (genetical recombination)]. Kyowa Kirin has been marketing G-Lasta® since 2014, and the drug is administered to patients undergoing chemotherapy to decrease the incidence of febrile neutropenia*.
With the G-Lasta® Subcutaneous Injection 3.6 mg BodyPod, the injection device is activated and attached to the patient's body at the hospital on the day of chemotherapy. Then, the drug is automatically administered approximately 27 hours later. In principle, G-Lasta® is typically administered at hospitals at least one day after chemotherapy. The newly developed combination product allows patients to skip the additional outpatient visit required for the administration of G-Lasta®, and helps reduce the burden on patients.
Terumo has developed the automated injection device of the G-Lasta® Subcutaneous Injection 3.6 mg BodyPod by leveraging its expertise in medical device engineering. Noritsugu Fujita, Executive Officer, Division President of Pharmaceutical Solutions comments, “We will continue to provide unique solutions to pharmaceutical companies to maximize the value of their drugs and contribute to increase patients’ quality of life”.
* Febrile neutropenia is a complication in patients receiving chemotherapy. It refers to when the patient has a fever with low neutrophil count and is at risk of serious infection.
Reference
About Pharmaceutical Solutions Division
https://www.terumo.com/business/pharmaceutical-solutions
https://www.terumo.com/business/pharmaceutical-solutions
About Terumo
Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.